Dublin, April 25, 2024 (GLOBE NEWSWIRE) -- The 'Diabetic Kidney Disease (DKD) - Market Insight, Epidemiology and Market Forecast - 2032' report has been added to ResearchAndMarkets.com's offering.Key Highlights In the 7MM, the United States accounted for the largest market size in 2022, with approximately USD 6,200 million.The disease is reported to occur in 20-50% of those living with diabetes and is the single most common cause of end-stage kidney disease (ESKD) in many populations.Current management strategies employ aggressive glycemic and blood pressure control combined with renin-angiotensin-aldosterone system-blocking agents to slow the worsening of kidney disease.For a long time, there were no drugs specific to DKD other than RAS inhibitors.

都柏林，2024年4月25日（环球通讯社）--“糖尿病肾病（DKD）-市场洞察力，流行病学和市场预测-2032”报告已添加到ResearchAndMarkets.com的产品中。主要亮点在这700万美元中，美国在2022年占据了最大的市场规模，约为6200万美元。据报道，该疾病发生在20-50%的糖尿病患者中，是许多人群中终末期肾病（ESKD）的最常见原因。目前的管理策略采用积极的血糖和血压控制以及肾素-血管紧张素-醛固酮系统阻断剂来减缓肾脏疾病的恶化。长期以来，除了RAS抑制剂外，没有针对DKD的特异性药物。

In 2019, a CREDENCE trial proved the efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors for DKD, adding a new treatment option.INVOKANA and FARXIGA are two of the approved SGLT2 inhibitors available in the US, Europe, and Japan for treating DKD. Moreover, recently, JARDIANCE has also gained approval in the US and Europe in 2023 for treating CKD patients with and without type-2 diabetes.Among novel treatments, mineralocorticoid receptor antagonists (MRA) are considered extremely promising.

2019年，一项CREDENCE试验证明了钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂对DKD的疗效，增加了一种新的治疗选择。INVOKANA和FARXIGA是美国，欧洲和日本可用于治疗DKD的两种批准的SGLT2抑制剂。此外，最近，JARDIANCE也于2023年在美国和欧洲获得批准，用于治疗患有和不患有2型糖尿病的CKD患者。在新的治疗方法中，盐皮质激素受体拮抗剂（MRA）被认为是非常有前途的。

In addition, Bayer's KERENDIA has been approved in the US in 2021 and in Europe and Japan in 2022 to treat adult patients with CKD associated with type 2 diabetes.Off-label therapies and generics occupy the major share of the current DKD market as they are cheaper and more easily accessible to patients, being a major barrier to newly developed drugs.A few therapies are also being investigated for the treatment of DKD.

此外，拜耳的KERENDIA已于2021年在美国获得批准，并于2022年在欧洲和日本获得批准，用于治疗与2型糖尿病相关的CKD成年患者。非标签疗法和仿制药占据了当前DKD市场的主要份额，因为它们更便宜，患者更容易获得，是新开发药物的主要障碍。一些治疗DKD的疗法也正在研究中。

Some key players involved in the development are Daiichi Sankyo (esaxerenone), ProKidney (REACT), Inversago Ph.

参与开发的一些关键参与者是Daiichi Sankyo（esaxerenone），ProKidney（REACT），Inversago Ph。